Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALKS 4510
- Development stage
- Phase 1
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALKS 4510 is an investigational, orally administered, small molecule agonist of the orexin 2 receptor, developed by Alkermes for central nervous system disorders. It is currently being evaluated in first-in-human phase 1 studies assessing its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ALKS 4510 is part of Alkermes' broader orexin agonist program and is anticipated to enter further clinical development targeting sleep and neuropsychiatric disorders. The precise clinical indications beyond CNS disorders have not yet been disclosed for this agent, but orexin 2 receptor agonists are being explored for conditions such as narcolepsy and idiopathic hypersomnia[1][3][4][5][6][9].
02
Targets
HCRTR2 (Orexin/hypocretin receptor type 2)
Beyond the preview
Go deeper on ALKS 4510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALKS 4510.